Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis.
Bhai S, Levine T, Moore D, Bowser R, Heim AJ, Walsh M, Shibani A, Simmons Z, Grogan J, Goyal NA, Govindarajan R, Hussain Y, Papsdorf T, Schwasinger-Schmidt T, Olney N, Goslin K, Pulley M, Kasarskis E, Weiss M, Katz SW, Moser S, Jabari D, Jawdat O, Statland J, Dimachkie MM, Barohn R; Neuromuscular Study Group and Western ALS Consortium Memantine ALS Study Group. Bhai S, et al. Among authors: heim aj. Muscle Nerve. 2025 Jan;71(1):63-72. doi: 10.1002/mus.28287. Epub 2024 Nov 7. Muscle Nerve. 2025. PMID: 39511965 Free PMC article. Clinical Trial.
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C; ORARIALS-01 trial team. Benatar M, et al. Lancet Neurol. 2024 Jul;23(7):687-699. doi: 10.1016/S1474-4422(24)00134-0. Epub 2024 May 20. Lancet Neurol. 2024. PMID: 38782015 Clinical Trial.
Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study.
Pasnoor M, Bril V, Levine T, Trivedi J, Silvestri NJ, Phadnis M, Katzberg HD, Saperstein DS, Wolfe GI, Herbelin L, Higgs K, Heim AJ, Statland JM, Barohn RJ, Dimachkie MM. Pasnoor M, et al. Among authors: heim aj. Eur J Neurol. 2023 May;30(5):1417-1424. doi: 10.1111/ene.15745. Epub 2023 Mar 6. Eur J Neurol. 2023. PMID: 36779862 Clinical Trial.
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
Machado PM, McDermott MP, Blaettler T, Sundgreen C, Amato AA, Ciafaloni E, Freimer M, Gibson SB, Jones SM, Levine TD, Lloyd TE, Mozaffar T, Shaibani AI, Wicklund M, Rosholm A, Carstensen TD, Bonefeld K, Jørgensen AN, Phonekeo K, Heim AJ, Herbelin L, Barohn RJ, Hanna MG, Dimachkie MM; Arimoclomol in IBM Investigator Team of the Neuromuscular Study Group. Machado PM, et al. Among authors: heim aj. Lancet Neurol. 2023 Oct;22(10):900-911. doi: 10.1016/S1474-4422(23)00275-2. Lancet Neurol. 2023. PMID: 37739573 Free article. Clinical Trial.
Methotrexate Polyglutamation in a Myasthenia Gravis Clinical Trial.
Pasnoor M, Heim AJ, Herbelin L, Statland J, Dimachkie MM, Becker M, Barohn RJ; Methotrexate in MG Investigators of the Muscle Group Study. Pasnoor M, et al. Among authors: heim aj. Kans J Med. 2020 Feb 26;13(Suppl 2):10-13. eCollection 2020. Kans J Med. 2020. PMID: 32256969 Free PMC article.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R, Swenson A, Ravits J, Jackson C, Burns TM, Trivedi J, Pioro EP, Caress J, Katz J, McCauley JL, Rademakers R, Malaspina A, Ostrow LW, Wuu J; CReATe Consortium. Benatar M, et al. Neurology. 2020 Jul 7;95(1):e59-e69. doi: 10.1212/WNL.0000000000009559. Epub 2020 May 8. Neurology. 2020. PMID: 32385188 Free PMC article.
Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential.
Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD. Wallach J, et al. Among authors: heim aj. Nat Commun. 2023 Dec 15;14(1):8221. doi: 10.1038/s41467-023-44016-1. Nat Commun. 2023. PMID: 38102107 Free PMC article.
Identification of 5-HT2A Receptor Signaling Pathways Responsible for Psychedelic Potential.
Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD. Wallach J, et al. Among authors: heim aj. bioRxiv [Preprint]. 2023 Jul 31:2023.07.29.551106. doi: 10.1101/2023.07.29.551106. bioRxiv. 2023. Update in: Nat Commun. 2023 Dec 15;14(1):8221. doi: 10.1038/s41467-023-44016-1 PMID: 37577474 Free PMC article. Updated. Preprint.
18 results